Meeting
2013 ASCO Annual Meeting
Phi-53: (NCI#7251): Phase I trial of belinostat (PXD101) in combination with 13-cis-retinoic acid (13c-RA) in advanced solid tumor malignancies—A California Cancer Consortium NCI/CTEP sponsored trial.
Authors
Thehang H. Luu
City of Hope, Duarte, CA
Thehang H. Luu , Paul Henry Frankel , Dean Lim , Mihaela C. Cristea , Jan Hendrik Beumer , Leonard Joseph Appleman , Heinz-Josef Lenz , David R. Gandara , Richard Piekarz , Edward M. Newman
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Developmental Therapeutics - Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics
Sub Track
Epigenetics
Clinical Trial Registration Number
NA
Citation
J Clin Oncol 31, 2013 (suppl; abstr 2526)
DOI
10.1200/jco.2013.31.15_suppl.2526
Abstract #
2526
Poster Bd #
14
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Interim results of a first-in-human phase 1 study of Q-1802, a CLDN18.2/PD-L1 bsABs, in patients with relapsed or refractory solid tumors.
First Author: Wang Yk
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Safety and preliminary efficacy of MIL93 in patients with advanced solid tumors: The monotherapy part of a phase 1 trial.
First Author: Jing Huang
Poster
2022 ASCO Annual Meeting
A phase I trial of elimusertib in combination with cisplatin or with cisplatin plus gemcitabine in advanced solid tumors with an emphasis on urothelial carcinoma.
First Author: Ryan Leibrandt
Poster
2020 ASCO Virtual Scientific Program
Phase I study of regorafenib and sildenafil in advanced solid tumors.
First Author: Andrew Stewart Poklepovic